Table 3.
Baseline characteristics of noradrenaline or phenylephrine (n = 550)
| Variable | Noradrenaline (n = 201) | Phenylephrine (n = 349) | p value | ||
|---|---|---|---|---|---|
| Missing | Missing | ||||
| Sex (male) | 97 (48%) | 182 (52%) | 0.215 | ||
| Age (years)* | 71 (31–95) | 72 (24–94) | 0.455 | ||
| ≥ 70 | 115 (58%) | 193 (57%) | |||
| Body mass index ≥ 30 kg/m2 | 39 (20%) | 82 (24%) | 0.153 | ||
| ASA classification | 0.519 | ||||
| ≥ 3 | 70 (35%) | 121 (35%) | |||
| Diabetes mellitus | 48 (24%) | 51 (15%) | n = 6 | 0.006 | |
| Intoxications | |||||
| Current smoker | 23 (12%) | n = 10 | 34 (11%) | n = 23 | 0.348 |
| Pack years ≥ 15 years | 41 (32%) | n = 12 | 70 (25%) | n = 27 | 0.060 |
| Alcohol intake ≥ 3 units/day | 12 (6%) | n = 9 | 14 (4%) | n = 17 | 0.219 |
| Steroid use (excl. inhalers) | 6 (3%) | 9 (3%) | 0.504 | ||
| Disease | n = 5 | 0.423 | |||
| Malignant | 171 (85%) | 296 (86%) | |||
| Benign | 30 (15%) | 48 (14%) | |||
| Neoadjuvant therapy | n = 6 | n = 19 | 0.051 | ||
| None | 167 (86%) | 305 (93%) | |||
| 5 × 5 radiotherapy | 16 (8%) | 11 (3%) | |||
| Chemotherapy | 6 (3%) | 8 (2%) | |||
| Chemoradiotherapy | 5 (3%) | 4 (1%) | |||
| Distance of tumor from AV < 15 cm | 25 (12%) | 28 (8%) | 0.027 | ||
| Pathological TNM stage | n = 7 | n = 7 | 0.129 | ||
| I (T1-2N0M0) | 62 (31%) | 141 (40%) | |||
| II (T3-4N0M0) | 58 (29%) | 60 (17%) | |||
| III (T1-4N1-2M0) | 41 (20%) | 79 (23%) | |||
| IV (T1-4N1-2M1) | 6 (3%) | 13 (4%) | |||
Bold values indicate significance of p value (p < 0.005)
Data are presented as number (%) unless stated otherwise
ASA American Society of Anesthesia score, TNM Tumor, node and metastasis classification, AV Anal verge
A p < 0.05 was considered statistically significant
*Data are presented as medians (range)